A chemical tool box defines mitotic and interphase roles for Mps1 kinase by Lan, Weijie & Cleveland, Don W.
The Rockefeller University Press    $30.00
J. Cell Biol. Vol. 190 No. 1  21–24
www.jcb.org/cgi/doi/10.1083/jcb.201006080 JCB 21
JCB: Comment
Mps1 is an essential mitotic kinase in organisms from yeast to 
man. Originally discovered in a yeast genetic screen for mutants 
producing monopolar spindles (Winey et al., 1991), Mps1’s pri-
mary role is in the mitotic checkpoint (Weiss and Winey, 1996; 
Abrieu et al., 2001; Stucke et al., 2002; Fisk and Winey, 2004). 
This checkpoint, also known as the spindle assembly checkpoint, 
prevents cell cycle advance from metaphase to anaphase before 
attachment of every chromosome to spindle microtubules. The 
signaling device for this safeguard mechanism is the unattached 
kinetochore, which generates one or more inhibitors of Cdc20, 
an essential activator of anaphase-promoting complex/cyclosome 
(APC/C), the E3 ubiquitin ligase which targets cyclin B and se-
curin for destruction (Figs. 1 and 2; Kops et al., 2005; Musacchio 
and Salmon, 2007). In the absence of a functional mitotic check-
point, as occurs when Mps1 function is lost, cells become rapidly 
aneuploid and subsequently die (Kops et al., 2005; Janssen et al., 
2009), observations which have lead to the proposal that Mps1 is 
an attractive anticancer drug target.
Three novel Mps1 inhibitors have been described this year. 
A first pair, Mps1-IN-1 and Mps1-IN-2, have half maximal 
inhibitory  concentrations  (IC50)  of  between  100  and  300  nM 
(Kwiatkowski et al., 2010). In this issue, two more Mps1 inhibitors 
are reported (Table I). Hewitt et al. describe AZ3146, which has 
an IC50 of 35 nM toward recombinant Mps1 and does not   
inhibit Cdk1 and Aurora B at that concentration. Concurrently, 
Santaguida et al. discover that reversine, a purine derivative named 
after its ability to promote dedifferentiation of C2C12 myoblasts 
into multipotent cells (Chen et al., 2004), is actually a highly   
potent Mps1 inhibitor. Although previously proposed to be an 
In this issue, three groups (Hewitt et al. 2010. J. Cell Biol. 
doi:10.1083/jcb.201002133; Maciejowski et al. 2010. 
J. Cell Biol. doi:10.1083/jcb.201001050; Santaguida 
et al. 2010. J. Cell Biol. doi:10.1083/jcb.201001036) 
use chemical inhibitors to analyze the function of the mi-
totic checkpoint kinase Mps1. These studies demonstrate 
that Mps1 kinase activity ensures accurate chromosome 
segregation through its recruitment to kinetochores of   
mitotic checkpoint proteins, formation of interphase and 
mitotic  inhibitors  of  Cdc20,  and  correction  of  faulty   
microtubule attachments.
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Aurora B inhibitor (D’Alise et al., 2008), reversine is the most 
potent of the Mps1 inhibitors with an IC50 of 3 nM toward full-
length Mps1 (Santaguida et al., 2010). It is also the most exhaus-
tively characterized for specificity, and it is 35 times more potent 
an inhibitor of Mps1 than of Aurora B. In addition, Mps1 inhibi-
tion by reversine is rapidly reversed after removal of the drug 
from culture media, a valuable experimental property which at-
tributes another meaning to the name.
Using a complementary approach, in this issue, Maciejowski 
et al. produced the highest selectivity in Mps1 inhibition by 
building human diploid cells in which the sole Mps1 gene con-
tained  a  mutation  that  resulted  in  an  enlarged ATP-binding 
pocket (frequently called a Shokat allele) that can accept (and 
be  inhibited  by)  a  bulky  purine  analogue  (3MB-PP1).  The 
modified Mps1 (termed Mps1-as), already reduced in activity 
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Figure  1.  Microtubule–kinetochore  attachments.  Four  types  of  kineto-
chore–microtubule attachments are highlighted. (A) Monotelic attachment 
with only one kinetochore attached. Unattached kinetochores produce the 
mitotic checkpoint inhibitor that delays advance to anaphase by inactivat-
ing Cdc20, an activator of the ubiquitin ligase APC/C. (B) Syntelic attach-
ment with both kinetochores attached to microtubules from the same pole. 
(C) Merotelic attachment with one kinetochore attached to microtubules 
from both poles. (D) Bioriented attachment (also known as amphitelic) 
with the two kinetochores of each chromatid pair attached to opposite 
spindle poles.
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kinase activity provided by this allele is sufficient for Mps1’s   
essential role.
In  contrast,  by  using  the  AZ3146  inhibitor,  Hewitt   
et al. (2010) found that Mps1 activity is required to recruit 
Mad1 to kinetochores but not maintain it there. Stably bound 
Mad1 forms a tight complex with closed Mad2 (C-Mad2) at 
unattached kinetochores, which serves as a template to dock an 
additional, initially open Mad2 conformer (O-Mad2; the latent 
inactive form that spontaneously binds Cdc20 very slowly). 
This produces a putative, transient kinetochore-bound inter-
mediate (I-Mad2) that can convert into C-Mad2 that is bound to 
Cdc20, thereby inactivating it (Fig. 2; Musacchio and Salmon, 
2007). Interestingly, Hewitt et al. (2010) report that recruitment 
of O-Mad2 to the C-Mad2–Mad1 template is blocked if Mps1 
is inhibited with AZ3146 after cells enter mitosis. Thus, both   
C-Mad2 and O-Mad2 molecules require Mps1 activity for load-
ing  at  kinetochores,  but  the  stably  bound  C-Mad2  does  not 
require continuing Mps1 activity. How Mps1 kinase activity 
controls the docking of O-Mad2 to the C-Mad2–Mad1 template 
is now a central, unresolved question (Fig. 2 B).
In addition to the generation of a Cdc20 inhibitor by   
unattached kinetochores in prometaphase, a Cdc20 inhibitor is 
generated in interphase so as to prevent immediate anaphase 
onset after mitotic entry, thereby providing time for newly as-
sembled kinetochores to generate their own mitotic checkpoint 
inhibitor. This premade inhibitor has been referred to as a timer 
(Meraldi et al., 2004), as the minimum length of mitosis is   
set by the time needed to inactivate it. Use of each of the Msp1 
by 90% relative to unmodified Mps1, could be highly selec-
tively inhibited by the addition of 3MB-PP1. Collectively, these 
new chemical tools have enabled dissection of the multiple sig-
naling pathways regulated by Mps1 in human cells and may 
mark a starting point for the development of therapeutic drugs 
targeting Mps1.
Each of the new Mps1 inhibitors overrides mitotic check-
point–mediated mitotic arrest in cells in which spindle assembly 
is  blocked  with  microtubule  inhibitors  (Hewitt  et  al.,  2010;   
Maciejowski et al., 2010; Santaguida et al., 2010). These data con-
firm an indispensible role for Mps1 kinase activity in the mitotic 
checkpoint (Abrieu et al., 2001; Dorer et al., 2005; Jones et al., 
2005). It should be noted that among the current and previous 
studies, there are marked discrepancies on exactly which of the 
checkpoint proteins require Mps1 activity for their kinetochore 
localization (Fig. 2 A and Table I). Our view is that these differ-
ences are likely due to the extent and timing of Mps1 inhibition, 
as well as the use of different cell types. Mps1’s role in the check-
point had previously been attributed to its requirement for kineto-
chore  recruitment  of  the  checkpoint  protein  Mad2  (Abrieu   
et al., 2001; Jelluma et al., 2008; Tighe et al., 2008; Kwiatkowski 
et al., 2010; Sliedrecht et al., 2010). In engineered human retinal 
pigment epithelial (RPE) cells (Maciejowski et al., 2010), all 
conserved mitotic checkpoint components, including Bub1, 
BubR1, Mad1, and Mad2, were evicted from kinetochores when 
Mps1 was inhibited or deleted. Also, all were recruited in the 
cells containing only the Mps1-as allele but to which no inhibi-
tor had been added, demonstrating that the 10% of normal   
Figure 2.  Mps1 functions at multiple steps to in-
hibit Cdc20–APC/C. (A) All three groups (Hewitt   
et al., 2010; Maciejowski et al., 2010; Santaguida   
et  al.,  2010)  demonstrate  that  at  unattached   
kinetochores, Mps1 kinase activity is required to 
recruit other mitotic checkpoint components, includ-
ing Mad1, Mad2, Bub1, BubR1, Bub3, and the 
Rod–Zw10–Zwilch complex. Discrepancies exist on 
exactly which components depend on Mps1 activ-
ity (see Table I for details). (B) Hewitt et al. (2010) 
show that Mps1 kinase activity maintains the recruit-
ment at unattached kinetochores of O-Mad2 to the 
stably bound Mad1–C-Mad2 template. The molecu-
lar mechanism is yet to be elucidated. Mps1 may 
dimerize and be activated by self phosphorylation 
at kinetochores followed by quick release into the 
cytosol. (C) Maciejowski et al. (2010) demonstrate 
that Mps1 kinase activity in the cytosol promotes 
the  assembly  and/or  prevents  the  disassembly   
of Cdc20–APC/C inhibitory complexes. Although 
the relative abundance and contribution of specific 
Cdc20–APC/C inhibitory complexes are unclear, 
all inhibit Cdc20 to prevent polyubiquitination of 
the key mitotic regulators cyclin B and securin by 
APC/C, an event which targets them for degrada-
tion as an irreversible trigger for anaphase entry.23 Chemical inhibition of Mps1 kinase • Lan and Cleveland
that fails to localize to kinetochores is sufficient to support   
the assembly of a Mad2–Cdc20 complex and delay anaphase   
onset. Because Mad2 and BubR1 can associate with and inhibit 
Cdc20 in vitro without Mps1 (Kulukian et al., 2009), Mps1 
may either catalyze these associations in vivo and/or inhibit a 
yet to be identified pathway that actively disassociates Mad2 
and BubR1 from Cdc20 (Fig. 2 C). An unresolved question is 
how cytosolic Mps1 is inhibited after checkpoint silencing at 
the kinetochore.
Using the chemical inhibitors, all three groups found that 
the kinase activity of human Mps1 is required for proper chromo-
some alignment and accurate chromosome segregation (Hewitt 
et al., 2010; Maciejowski et al., 2010; Santaguida et al., 2010), 
inhibitors has revealed that Mps1 inhibition shortens mitosis 
(Table I). Most striking among these, inhibition of Mps1-as 
with 3MB-PP1 shortens mitosis in human RPE cells from 42 
to 12 min (Maciejowski et al., 2010). This dramatic accelera-
tion of mitosis supports Mps1 as a component needed for pro-
duction of the interphase-produced M phase timer, in addition 
to Mad2 and BubR1 that directly bind Cdc20.
Although the exact molecular constituents of either the 
mitotic or interphase Cdc20 inhibitors are yet to be defined 
(Fig. 2 C), Maciejowski et al. (2010) found that the amounts of 
Mad2 and BubR1 associated with Cdc20 are significantly   
reduced after Mps1 inhibition in both interphase and mitotic 
cells. Furthermore, they found that a truncated Mps1 mutant 
Table I.  Summary of studies using chemical inhibitors of human Mps1 kinase activity
Property Studies
Hewitt et al., 2010 Kwiatkowski et al., 2010 Santaguida et al., 
2010
Maciejowski et al., 
2010
Sliedrecht et al., 
2010
Tighe et al., 
2008
Inhibitor AZ3146 Mps1-IN-1 Mps1-IN-2 Reversine 3MB-PP1 23-dMB-PP1 1-NM-PP1
Structure
IC50 (nM)
a 35 370 145 3/6
b ND ND ND
Conc. used in 
cell (µM)
2 10 10 0.5 10 1 10
Drug target Endogenous Mps1 Endogenous Mps1 Endogenous Mps1
c Endogenous 
Mps1
d
Mps1-as
e Mps1-as
e Mps1-as
e
Approach Inhibitor; siRNA Inhibitor;  
stable shRNA
Inhibitor;  
stable shRNA
Inhibitor;  
siRNA
Gene knockout + 
stable transgene
stable shRNA + 
stable transgene
shRNA +  
transgene
Cell line used  HeLa U2OS/HCT116/
HeLa/RPE1
U2OS HeLa hTERT-RPE1 U2OS/HCT116 HeLa
TMitosis (min)
f 90 ND ND 45 42 22/18 ND
TMitosis+Inhibitor (min) 32 45 ND 30 12 12/10 36
Kinetochore 
localization 
inhibited
g
O-Mad2/CENP-E Mad2/Mad1 ND Mad1/Spindly/
Rod/Zw10/
Zwilch
Mad2/Mad1/
Bub1/BubR1/
Zw10/Plk1/ 
CENP-E/pH2A/
Sgo1
Mad2/Mad1 
Bub1/Cdc20
Mad2
Kinetochore 
localization 
not inhibited
Mad1
h/Zwilch
h 
pCENP-A/Aurora 
B/pAurora B/ACA
CREST ND Bub1/BubR1/
KNL1/Mis12/
Ndc80/Zwint/
Aurora B/
pCENP-A/ 
CENP-C/CREST
Ska3/Ndc80/
KNL1/Zwint/
CENP-A/ 
Aurora B/
INCENP/CREST
CENP-E/BubR1/
ACA
Mad1/ACA
Chromosome 
misalignment
ND Yes ND Yes Yes Yes ND
Defect in error 
correction 
Yes NA ND Yes ND Yes ND
Affect Aurora B 
kinase activity 
No Yes ND No (at 0.5 µM) No Yes ND
Conc., concentration.
aThe half maximal inhibitory concentration.
bFor full-length and kinase domain Mps1, respectively.
cBinds Plk1 with higher affinity.
dInhibits Aurora B with an IC50 of 98 nM.
eAnalogue-sensitive Mps1.
fTime cells spend in mitosis.
gScoring >50% reduction of signal intensity.
hDepends on when drugs are applied.JCB • VOLUME 190 • NUMBER 1 • 2010   24
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in  agreement  with  previous  studies  using  short  hairpin  RNA 
(shRNA) to reduce Mps1 (Jelluma et al., 2008; Tighe et al., 2008).   
In particular, correction of syntelic attachments, in which both 
kinetochores of a mitotic chromatid pair are attached to the   
same pole (Fig. 1 B), are inhibited in the absence of Mps1 kinase 
activity (Hewitt et al., 2010; Maciejowski et al., 2010; Santaguida 
et al., 2010), as previously shown in yeast (Maure et al., 2007).   
It has been proposed that Mps1 acts upstream of Aurora B to cor-
rect syntelic attachments (Jelluma et al., 2008; Sliedrecht et al., 
2010). However, all three current studies failed to detect changes 
of Aurora B activity upon Mps1 inhibition; instead, Santaguida   
et al. (2010) and Hewitt et al. (2010) found that the kinetochore 
localization of Mps1 depends on Aurora B activity and propose 
that Aurora B acts upstream of Mps1. Indeed, consideration of   
the divergent outcomes for which kinase comes first (Table I) 
makes it unlikely, at least in our view, that there is a strictly linear 
pathway with one kinase upstream of the other; rather, there is 
likely to be a network nature of mitotic kinase signaling. Addi-
tionally, Mps1 and Aurora B kinase activities may converge on a 
common substrate or substrates. The kinetochore motor CENP-E 
is a good candidate for such a target, as it is required for chromo-
some congression and is phosphorylated by both Mps1 (Espeut 
et al., 2008) and Aurora B (Kim et al., 2010). Aurora B is also 
required for correcting merotelic attachment errors (Fig. 1 C;   
Cimini et al., 2006; Knowlton et al., 2006), a condition which 
does not occur in budding yeast. It remains to be tested whether 
human Mps1 also corrects this type of attachment error and, if so, 
whether it partners with Aurora B. The chemical tools recently 
developed should greatly facilitate the field to dissect out these 
underlying mechanisms.
Beyond an understanding of how Mps1 functions at a mo-
lecular level, an ultimate goal is the design of better anticancer 
drugs. The current Mps1 inhibitors serve as a starting point to di-
rectly evaluate whether Mps1 can be used as an effective anticancer 
drug target. A caveat of this approach is the requirement for >90% 
inhibition before any observable mitotic phenotype. Nevertheless, 
initial studies have demonstrated that inhibiting Mps1 with chemi-
cal inhibitors kills cultured tumor cells (Kwiatkowski et al., 2010; 
Sliedrecht et al., 2010). We wait to see if this promise holds true in 
clinical settings.
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